TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has provided an update.
Shanghai Henlius Biotech, Inc. has entered into collaboration agreements with Avanc Pharma to commercialize Fovinaciclib Citrate Capsules, a CDK4/6 inhibitor for HR+ and HER2-breast cancer, in China. This collaboration aligns with Henlius’s strategic focus on breast cancer treatments and is expected to enhance its product offerings and revenue potential. The agreements involve connected transactions under Hong Kong’s Listing Rules, with specific financial and operational implications for Henlius, but they are exempt from independent shareholders’ approval due to the transaction size.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$74.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a biotechnology company based in China, focusing on the development and commercialization of cancer treatment products. The company specializes in breast cancer therapies, leveraging its existing commercialization team and resources to expand its product pipeline and revenue scale.
Average Trading Volume: 1,465,995
Technical Sentiment Signal: Buy
Current Market Cap: HK$37.77B
Find detailed analytics on 2696 stock on TipRanks’ Stock Analysis page.